Tesamorelin
- Mechanism summary
- It is studied as a growth hormone releasing hormone receptor agonist. The trials report growth hormone and insulin like growth factor 1 measurements. This page does not turn those measurements into a clinical instruction.
- Research context
- Tesamorelin is a synthetic analog of growth hormone releasing hormone. Randomized trials have enrolled adults with HIV and abdominal fat accumulation and recorded visceral fat, liver fat, and laboratory markers. A 2014 randomized trial recorded visceral fat and liver fat. A pooled analysis of two earlier trials and a 2008 report recorded abdominal fat and the events observed over a longer interval. This summary does not interpret those measurements as a promise of results.
- Regulatory status
- Drugs@FDA records the approval of EGRIFTA (tesamorelin for injection) on November 10, 2010, under application 022505. Drugs@FDA states that this former NDA was deemed to be a BLA on March 23, 2020, and lists its products with a prescription marketing status. The most recent labeling posted under that application, revised in March 2025, is for EGRIFTA WR and states that it is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. That approval covers the EGRIFTA products under that application and their labeled use. It is not an approval of other preparations containing tesamorelin.
- Primary sources

